LSA
RVNC

Leonteq Securities AG’s Revance Therapeutics, Inc. RVNC Stock Holding History

Leonteq Securities AG’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$59.3K – 1230
2021
Q2 		$59.3K Buy
+2,000
New +$57.7K ﹤0.01% 811

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Leonteq Securities AG's RVNC Position: Q3 2021 in Review

Leonteq Securities AG sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2021, closing a stake of 2,000 shares — an estimated $59.3K sold.

Leonteq Securities AG first reported a position in RVNC in Q2 2021 and held it in 1 quarter. The position peaked at $59.3K in Q2 2021. 158 funds tracked by Wall St. Rank hold RVNC as of Q3 2021.

  • Leonteq Securities AG reported no remaining Revance Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Leonteq Securities AG sold 2,000 Revance Therapeutics, Inc. shares in Q3 2021, an estimated $59.3K.
  • Leonteq Securities AG first reported a position in Revance Therapeutics, Inc. in Q2 2021 and held it in 1 quarter.
  • Leonteq Securities AG's Revance Therapeutics, Inc. position peaked at $59.3K in Q2 2021.
  • 158 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2021.

Based on Leonteq Securities AG's 13F filing for Q3 2021, filed 26 Mar 2026.